A 31-year-old patient in remission of acute lymphoblastic leukaemia (ALL), receiving oral maintenance chemotherapy (6-mercaptopurine, methotrexate (MTX), cyclophosphamide), developed a monoclonal, Epstein-Barr virus (EBV)-related lymphoproliferative disorder (LPD). Treatment consisted of excisional biopsy and the discontinuation of maintenance chemotherapy. To our knowledge, this is the first such report in an adult. The histological similarity to previous reports of 'lymphomatoid granulomatosis' following paediatric ALL suggests that they are the same disease. MTX may play a central role in the development of LPD in this setting. Although it is a rare complication of ALL, EBV-related LPD should be considered in patients who develop lymphadenopathy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2141.1999.01593.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The novel CD16A/anti-CD3 bifunctional protein, eCD16A/anti-CD3-BFP, redirects T cell cytotoxicity toward antibody-bound target cells.
Hum Vaccin Immunother
December 2025
Department of Research and Development, ManySmart Therapeutics, Taipei, Taiwan.
Monoclonal antibodies enhance innate immunity, while bispecific T cell engager antibodies redirect adaptive T cell immunity. To stimulate both innate and adaptive mechanisms, we created a bifunctional eCD16A/anti-CD3-BFP adapter protein for combined use with clinically approved monoclonal IgG1 antibodies. The adaptor protein contains the extracellular domain of the human CD16A high-affinity variant, which binds the Fc domain of IgG1 antibodies, and an anti-human CD3 single-chain variable fragment that redirects T cell cytotoxicity.
View Article and Find Full Text PDFPrimary gastric T-cell lymphomas (PGTL) are exceedingly rare with an estimated incidence of 0.0091 per 100,000 person-years, affecting mainly elderly males. PGTL can present with a variety of gastrointestinal symptoms, but patients only rarely present with perforation.
View Article and Find Full Text PDFThe Value of a Pet Scan in Selecting the Best Lymph Node to Biopsy, and Confirming the Diagnosis of Idiopathic Multicentric Castleman Disease with HLH And EBV Viremia in a Previously Healthy Adult.
Eur J Case Rep Intern Med
November 2024
Research Institute of the McGill University Health Centre, Montreal, Canada.
Introduction: Castleman disease (CD) is a rare lymphoproliferative disorder having a variegated clinical presentation. Diagnosis of the idiopathic HIV- and HHV8-negative multicentric CD (iMCD) subtype poses a challenge given its non-specific clinical manifestations. iMCD presents as diffuse lymphadenopathy with inflammatory manifestations, primarily driven by interleukin-6 (IL-6).
View Article and Find Full Text PDFNeoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
December 2024
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, and Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address:
Article Synopsis
- The study investigates the effects of the PD-1 inhibitor toripalimab combined with chemoradiotherapy on patients with advanced nasopharyngeal carcinoma, particularly those with high EBV DNA levels, to see if it reduces recurrence risk compared to placebo.* -
- Conducted at Sun Yat-sen University Cancer Centre in China, 150 eligible patients were randomly assigned to receive either toripalimab or a placebo before and after chemoradiotherapy, focusing on the 2-year progression-free survival rate as the main outcome measure.* -
- Initial findings suggest that most of the participants were male (77%), and by the latest follow-up, the median progression-free survival period was approximately 37.8 months,
Use of antibodies against Epstein-Barr virus nuclear antigen 1 for detection of cellular proteins with monomethylated arginine residues that are potentially involved in viral transformation.
Arch Virol
November 2024
Center of Human and Molecular Biology (ZHMB), Institute of Human Genetics, Saarland University (USAAR), Kirrbergerstraße, Haus 60, Building 60, D-66421, Homburg/Saar, Germany.
Epstein-Barr virus nuclear antigen 1 (EBNA1) contains two arginine-glycine (RG) repeats that contain symmetric/asymmetric dimethylarginine (SDMA/ADMA) and monomethylarginine (MMA) residues. We generated mouse monoclonal antibodies directed against a monomethylated GRGRGG-containing repeat located between amino acids 328 and 377 of EBNA1. In addition to detecting MMA-modified EBNA1, we also had the goal of identifying cellular proteins that bind to MMA-modified EBNA1 in EBV-positive Raji cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!